BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - GSK plc (GSK, GSK.L) announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli, or dostarlimab monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instability-high/mismatch repair deficient locally advanced rectal cancer. In an exploratory analysis, 76% of evaluable patients achieved a complete response to dostarlimab alone. No disease recurrences have been reported among responders to date after a median follow-up of more than two years.
Separately, GSK plc announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, or Mo-Rez in platinum-resistant ovarian cancer. Results showed clinically meaningful and durable responses at >13 months follow-up, building on initial data in platinum-resistant ovarian cancer announced earlier in the current year. Mo-Rez achieved a confirmed objective response rate of 62%, with a median duration of response of 12.2 months at the selected phase III dose of 5.8 mg/kg. Median progression-free survival was 11.1 months.
At last close on LSE, GSK shares were trading at 1,893.28 pence.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
